Rizatriptan Benzoate NDC 0093-7472

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-7472Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-7472Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0093-7472-43	00093747243	18 BLISTER PACK in 1 BOX (0093-7472-43) / 1 TABLET in 1 BLISTER PACK (0093-7472-19)Marketed from Feb 12, 2013

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rizatriptan Benzoate
Generic name (nonproprietary): rizatriptan benzoate
Active ingredients: Rizatriptan benzoate — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077263
Marketing start: Feb 12, 2013
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 0093-7472_fe55c129-f82a-46c6-add0-e9f1d405eec6SPL ID fe55c129-f82a-46c6-add0-e9f1d405eec6SPL set ID 4ef60c83-ba48-4134-968b-13800ea9b7f2RxCUI 312840, 314209UNII WR978S7QHH
Pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400093747243 followed by a unit qualifier and the quantity

Package 00093-7472-43. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 1, 2019.

Indications (excerpt from the label)

Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [ see Contraindications ( 4 ) ]. Rizatriptan benzoate tablets are not indic…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077263

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077263
Product	Strength	Form · route	Labeler	Product NDC
Rizatriptan Benzoate	Rizatriptan benzoate 5 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0093-7471